We studied the effects of difluoromethylornithine (DFMO), an experimental drug that inhibits the biosynthesis of natural polyamines, on anti-DNA antibody production, immunoglobulin synthesis, proteinuria, and blood urea nitrogen (BUN) in lupus-prone female NZB/W mice. Administration of 1% of the drug in drinking water reduced anti-DNA antibody levels by about 80% of that of untreated mice of the same strain. There was a reduction of IgG and IgA levels in older DFMO treated mice, whereas IgM level was not affected. Proteinuria and BUN were also significantly reduced in treated mice. Moreover, DFMO treatment reduced the concentration of putrescine and spermidine in spleen cells. Our results suggest that polyamine biosynthesis inhibition by DFMO may provide a new approach to the treatment of lupus.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Chronic Low-Level IFN-γ Expression Disrupts Mitochondrial Complex I Activity in Renal Macrophages: An Early Mechanistic Driver of Lupus Nephritis Pathogenesis.
Int J Mol Sci
December 2024
Department of Food Science and Nutrition, Kyungpook National University, Daegu 41566, Republic of Korea.
Article Synopsis
- Mitochondrial dysfunction and macrophage dysregulation are important in autoimmune diseases, but how they connect is not fully understood.
- The study focuses on the role of chronic low-level interferon-gamma (IFN-γ) using a mouse model with lupus-like symptoms, finding that this condition suppresses mitochondrial function, especially in the kidneys.
- It suggests that restoring mitochondrial function could improve macrophage activity and provide new targets for treating autoimmune diseases like lupus nephritis.
Therapeutic effects of extracellular vesicles derived from mesenchymal stem cells primed with disease-conditioned-immune cells in systemic lupus erythematosus.
Arthritis Res Ther
November 2024
GenNBio Inc, 80, Deurimsandan 2-ro, Cheongbuk-eup, Pyeongtaek-si, Gyeonggi-do, 17796, Republic of Korea.
Article Synopsis
- Systemic lupus erythematosus (SLE) is a chronic, incurable autoimmune disease, prompting the need for effective treatments, such as using extracellular vesicles (EV) from mesenchymal stem cells (iMSCs) primed with immune cell media.
- In the study, female NZB/W F1 mice were divided into three groups to assess the effects of CM-EV and ASC-EV treatments compared to a control group, with assessment done over 36 weeks.
- Results showed that CM-EV treatment enhanced survival rates, reduced harmful antibodies, and improved kidney health, while both EV types decreased pro-inflammatory macrophages, indicating their potential in modulating SLE’s immune response.
Neuropilin-1 as a Key Molecule for Renal Recovery in Lupus Nephritis: Insights from an NZB/W F1 Mouse Model.
Int J Mol Sci
October 2024
Rheumatology Research Group-Lupus Unit, Vall d'Hebrón University Hospital, Vall d'Hebrón Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.
Article Synopsis
- - Systemic lupus erythematosus (SLE) is an autoimmune disease affecting many organs, with lupus nephritis (LN) impacting 40-50% of patients and potentially leading to serious kidney complications like end-stage renal disease (ESRD).
- - This study investigates the role of neuropilin-1 (NRP-1), a receptor in kidney tissue, as a biomarker for kidney recovery in LN using a mouse model, demonstrating a significant increase in NRP-1 levels over time.
- - High urinary NRP-1 levels (above 34.40 ng/mL) were strongly associated with positive renal outcomes, highlighting NRP-1's potential as a reliable biomarker for kidney recovery in
Cluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis.
Front Immunol
October 2024
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Article Synopsis
- CD44 is a glycoprotein linked to kidney inflammation and fibrosis, specifically studied in a mouse model for lupus nephritis (LN) and in human patients with active LN.
- The research showed that CD44 was absent in healthy kidneys but expressed in kidney cells of LN patients, and treatment with anti-CD44 antibodies improved kidney health in mice by reducing immune cell infiltration and fibrosis markers.
- Serum CD44 levels increased before clinical symptoms of renal flare in patients, effectively distinguishing those with active LN from healthy individuals and other kidney-related conditions.
Article Synopsis
- Lanthionine synthetase C-like 2 (LANCL2) is identified as a key immunoregulatory target in treating autoimmune diseases like systemic lupus erythematosus (SLE), with the investigational drug NIM-1324 aimed at improving patient outcomes.
- In laboratory models, mice lacking LANCL2 exhibited severe symptoms of inflammation, while treatment with NIM-1324 enhanced regulatory T cell populations and reduced harmful inflammatory T cells, leading to overall better health markers.
- NIM-1324 also showed efficacy in human immune cells from SLE patients, lowering pro-inflammatory cytokines and supporting a more balanced immune response, indicating its potential as a therapeutic option.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!